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In the molecule of the title compound, C14H16O3, all non-H
atoms except for one methyl C atom lie on a crystallographic
mirror plane. The conformation with respect to the C C
bond [1.3465 (12) A ˚ ]i strans. In the crystal, molecules are
linked via C—HO hydrogen bonds into C(5) chains
propagating along [100].
Related literature
For general background to and the pharmacological activities
of the title compound, see: Pessah et al. (2009); Jain (2005);
Medina et al. (2005). For the preparation of the title
compound, see: Aboul-Enein et al. (2012). For the stability of
the temperature controller used for the data collection, see:







a = 6.5305 (1) A ˚
b = 6.6798 (1) A ˚
c = 13.7264 (2) A ˚
  = 96.676 (1)
V = 594.72 (2) A ˚ 3
Z =2
Mo K  radiation
  = 0.09 mm
1
T = 100 K
0.42  0.32  0.25 mm
Data collection




Tmin = 0.963, Tmax = 0.978
8645 measured reﬂections
2336 independent reﬂections











All H-atom parameters reﬁned
 max = 0.48 e A ˚ 3
 min = 0.28 e A ˚ 3
Table 1
Hydrogen-bond geometry (A ˚ , ).
D—HAD —H HAD AD —HA
C2—H2AO2
i 0.95 (2) 2.56 (2) 3.5092 (12) 179 (1)
Symmetry code: (i) x  1;y;z.
Data collection: APEX2 (Bruker, 2009); cell reﬁnement: SAINT
(Bruker, 2009); data reduction: SAINT; program(s) used to solve
structure: SHELXTL (Sheldrick, 2008); program(s) used to reﬁne
structure: SHELXTL; molecular graphics: SHELXTL; software used
to prepare material for publication: SHELXTL and PLATON (Spek,
2009).
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(E)-1-(1,3-Benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-one
Hoong-Kun Fun, Ching Kheng Quah, Mohamed I. Attia, Mohammed F. El-Behairy and Omar A. 
Al-Deeb
Comment 
Epilepsy is a group of serious disorders of the brain characterized by excessive temporary neuronal discharge resulting in 
recurrent unprovoked seizures (Pessah et al., 2009). It affects approximately 1% of mankind and the majority of cases are 
in the developing countries (Jain, 2005; Medina et al., 2005). It affects about 50 million people worldwide, 1 person in 50 
will develop epilepsy at some time in his life and 1 in 20 will have a single epileptic seizure. Despite the development of 
new methods of seizure control, chronic administration of antiepileptic drugs (AEDs) remains the treatment of choice. 
However, the number of non-responding patients is as high as 30% and chronic medication with currently available AEDs 
may result in severe side-effects and undesired drug interactions. That is why in recent years intensive research has been 
carried out aiming at the development of new therapeutic strategies in epilepsy. The title compound is the precursor of the 
recently marketed antiepileptic drug, Stiripentol. Reduction of the title compound will give Stiripentol.
The title molecule, Fig. 1, is lying on the mirror plane (symmetry code: x, -y + 3/2, z). The (1E)-1-(1,3-benzodioxol-5-
yl)pent-1-en-3-one moiety (O1–O3/C1–C12) is exactly planar as it lies on a mirror plane. The title compound exists in 
trans configuration with respect to the C8═C9 bond [1.3465 (12) Å].
In the crystal structure, Fig. 2, molecules are linked via C2—H2A···O2 hydrogen bonds (Table 1) into chains along 
[100].
Experimental 
A 50% aqueous solution of KOH (78.5 ml) was added to a stirred solution of piperonal (11.0 g, 0.074 mol) and 
pinacolone (10.2 ml, 7.4 g, 0.074 mol) in methanol (200 ml). The reaction mixture was stirred and heated at 343 K for 5 
h. The reaction mixture was cooled to room temperature and diluted with water (150 ml). The precipitated solid was 
filtered off, washed with water (50 ml) and air dried to afford the title compound which was recrystallized from ethanol 
as colourless blocks, m.p. = 366 K (Aboul-Enein et al., 2011).
Refinement 
All H atoms were located in a difference Fourier map and refined freely with C—H = 0.952 (17)–1.026 (16) Å.
Computing details 
Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT (Bruker, 2009); 
program(s) used to solve structure: SHELXTL (Sheldrick, 2008); program(s) used to refine structure: SHELXTL 
(Sheldrick, 2008); molecular graphics: SHELXTL (Sheldrick, 2008); software used to prepare material for publication: 
SHELXTL (Sheldrick, 2008) and PLATON (Spek, 2009).supplementary materials
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Figure 1
The molecular structure of the title compound showing 50% probability displacement ellipsoids for non-H atoms. Suffix 
A = symmetry code (x, 3/2 - y, z). supplementary materials
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Figure 2
The crystal structure of the title compound, viewed along the b axis. H atoms not involved in hydrogen bonds (dashed 






Hall symbol: -P 2yb
a = 6.5305 (1) Å
b = 6.6798 (1) Å
c = 13.7264 (2) Å
β = 96.676 (1)°
V = 594.72 (2) Å3
Z = 2
F(000) = 248
Dx = 1.297 Mg m−3
Mo Kα radiation, λ = 0.71073 Å
Cell parameters from 4988 reflections
θ = 3.0–32.7°
µ = 0.09 mm−1supplementary materials
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T = 100 K
Block, colourless
0.42 × 0.32 × 0.25 mm
Data collection 
Bruker SMART APEXII CCD 
diffractometer
Radiation source: fine-focus sealed tube
Graphite monochromator
φ and ω scans
Absorption correction: multi-scan 
(SADABS; Bruker, 2009)
Tmin = 0.963, Tmax = 0.978
8645 measured reflections
2336 independent reflections
2117 reflections with I > 2σ(I)
Rint = 0.018













Primary atom site location: structure-invariant 
direct methods
Secondary atom site location: difference Fourier 
map
Hydrogen site location: inferred from 
neighbouring sites
All H-atom parameters refined
w = 1/[σ2(Fo
2) + (0.0687P)2 + 0.0862P] 




Δρmax = 0.48 e Å−3
Δρmin = −0.28 e Å−3
Special details 
Experimental. The crystal was placed in the cold stream of an Oxford Cryosystems Cobra open-flow nitrogen cryostat 
(Cosier & Glazer, 1986) operating at 100.0 (1) K.
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance 
matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, 
conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is 
used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based 
on F2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
xy z U iso*/Ueq
O1 −0.08309 (10) 0.7500 0.73220 (5) 0.01756 (15)
O2 0.23387 (11) 0.7500 0.67099 (5) 0.02109 (16)
O3 −0.10343 (12) 0.7500 0.11962 (5) 0.0284 (2)
C1 −0.27995 (14) 0.7500 0.46990 (7) 0.01734 (18)
C2 −0.29527 (14) 0.7500 0.57113 (7) 0.01815 (18)
C3 −0.11215 (14) 0.7500 0.63184 (6) 0.01431 (16)
C4 0.13580 (14) 0.7500 0.75950 (6) 0.01731 (17)
C5 0.07776 (13) 0.7500 0.59505 (6) 0.01401 (16)
C6 0.09473 (13) 0.7500 0.49674 (6) 0.01446 (16)
C7 −0.08980 (13) 0.7500 0.43188 (6) 0.01338 (16)
C8 −0.08717 (14) 0.7500 0.32577 (6) 0.01474 (16)
C9 0.08137 (14) 0.7500 0.27781 (6) 0.01558 (17)
C10 0.06467 (14) 0.7500 0.16901 (6) 0.01549 (17)supplementary materials
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C11 0.26558 (13) 0.7500 0.12174 (6) 0.01458 (16)
C12 0.21897 (17) 0.7500 0.01018 (7) 0.0271 (2)
C13 0.39093 (12) 0.56198 (11) 0.15410 (6) 0.02431 (16)
H1A −0.406 (3) 0.7500 0.4256 (12) 0.032 (4)*
H2A −0.424 (3) 0.7500 0.5974 (12) 0.031 (4)*
H4A 0.1728 (15) 0.6272 (15) 0.7976 (7) 0.018 (2)*
H6A 0.239 (2) 0.7500 0.4738 (11) 0.025 (4)*
H8A −0.220 (3) 0.7500 0.2883 (12) 0.034 (4)*
H9A 0.218 (3) 0.7500 0.3117 (12) 0.032 (4)*
H12A 0.138 (2) 0.631 (2) −0.0117 (9) 0.041 (3)*
H12B 0.350 (3) 0.7500 −0.0180 (12) 0.030 (4)*
H13A 0.4241 (18) 0.5522 (18) 0.2246 (9) 0.034 (3)*
H13B 0.3154 (19) 0.4437 (18) 0.1331 (8) 0.033 (3)*
H13C 0.5215 (17) 0.5639 (16) 0.1247 (8) 0.026 (3)*
Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
O1 0.0164 (3) 0.0258 (3) 0.0112 (3) 0.000 0.0045 (2) 0.000
O2 0.0137 (3) 0.0385 (4) 0.0113 (3) 0.000 0.0022 (2) 0.000
O3 0.0141 (3) 0.0557 (6) 0.0153 (3) 0.000 0.0012 (2) 0.000
C1 0.0124 (4) 0.0258 (4) 0.0141 (4) 0.000 0.0029 (3) 0.000
C2 0.0133 (4) 0.0272 (4) 0.0149 (4) 0.000 0.0054 (3) 0.000
C3 0.0147 (4) 0.0167 (4) 0.0122 (3) 0.000 0.0046 (3) 0.000
C4 0.0173 (4) 0.0231 (4) 0.0119 (3) 0.000 0.0032 (3) 0.000
C5 0.0123 (3) 0.0173 (4) 0.0127 (3) 0.000 0.0027 (3) 0.000
C6 0.0127 (3) 0.0187 (4) 0.0126 (3) 0.000 0.0040 (3) 0.000
C7 0.0127 (3) 0.0157 (4) 0.0123 (3) 0.000 0.0034 (3) 0.000
C8 0.0142 (3) 0.0180 (4) 0.0123 (3) 0.000 0.0030 (3) 0.000
C9 0.0142 (4) 0.0210 (4) 0.0119 (3) 0.000 0.0029 (3) 0.000
C10 0.0136 (4) 0.0206 (4) 0.0127 (3) 0.000 0.0036 (3) 0.000
C11 0.0137 (3) 0.0178 (4) 0.0130 (3) 0.000 0.0045 (3) 0.000
C12 0.0222 (5) 0.0465 (7) 0.0136 (4) 0.000 0.0065 (3) 0.000
C13 0.0235 (3) 0.0215 (3) 0.0302 (3) 0.0061 (3) 0.0129 (3) 0.0056 (3)
Geometric parameters (Å, º) 
O1—C3 1.3685 (10) C7—C8 1.4587 (12)
O1—C4 1.4350 (11) C8—C9 1.3465 (12)
O2—C5 1.3706 (11) C8—H8A 0.956 (18)
O2—C4 1.4378 (11) C9—C10 1.4848 (12)
O3—C10 1.2214 (11) C9—H9A 0.960 (17)
C1—C7 1.4018 (12) C10—C11 1.5298 (12)
C1—C2 1.4046 (12) C11—C12 1.5262 (13)
C1—H1A 0.967 (17) C11—C13i 1.5363 (9)
C2—C3 1.3758 (13) C11—C13 1.5363 (9)
C2—H2A 0.952 (17) C12—H12A 0.985 (13)
C3—C5 1.3924 (11) C12—H12B 0.980 (17)
C4—H4A 0.988 (10) C13—H13A 0.969 (12)
C5—C6 1.3668 (11) C13—H13B 0.958 (12)supplementary materials
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C6—C7 1.4125 (12) C13—H13C 0.985 (11)
C6—H6A 1.026 (16)
C3—O1—C4 106.27 (6) C9—C8—H8A 118.6 (10)
C5—O2—C4 106.12 (7) C7—C8—H8A 115.0 (10)
C7—C1—C2 122.43 (8) C8—C9—C10 121.54 (8)
C7—C1—H1A 119.6 (10) C8—C9—H9A 122.2 (10)
C2—C1—H1A 117.9 (10) C10—C9—H9A 116.3 (10)
C3—C2—C1 116.25 (8) O3—C10—C9 120.97 (8)
C3—C2—H2A 120.9 (10) O3—C10—C11 121.63 (8)
C1—C2—H2A 122.9 (10) C9—C10—C11 117.40 (7)
O1—C3—C2 128.23 (8) C12—C11—C10 110.16 (8)
O1—C3—C5 109.87 (8) C12—C11—C13i 109.12 (5)
C2—C3—C5 121.90 (8) C10—C11—C13i 109.38 (5)
O1—C4—O2 107.90 (7) C12—C11—C13 109.12 (5)
O1—C4—H4A 108.2 (6) C10—C11—C13 109.38 (5)
O2—C4—H4A 110.0 (6) C13i—C11—C13 109.67 (8)
C6—C5—O2 127.76 (8) C11—C12—H12A 110.1 (7)
C6—C5—C3 122.41 (8) C11—C12—H12B 108.4 (10)
O2—C5—C3 109.83 (7) H12A—C12—H12B 110.1 (9)
C5—C6—C7 117.46 (8) C11—C13—H13A 113.2 (7)
C5—C6—H6A 119.0 (9) C11—C13—H13B 110.4 (7)
C7—C6—H6A 123.5 (9) H13A—C13—H13B 107.0 (10)
C1—C7—C6 119.55 (8) C11—C13—H13C 109.2 (6)
C1—C7—C8 119.05 (8) H13A—C13—H13C 107.8 (9)
C6—C7—C8 121.41 (7) H13B—C13—H13C 109.1 (9)
C9—C8—C7 126.39 (8)
C7—C1—C2—C3 0.0 C2—C1—C7—C6 0.0
C4—O1—C3—C2 180.0 C2—C1—C7—C8 180.0
C4—O1—C3—C5 0.0 C5—C6—C7—C1 0.0
C1—C2—C3—O1 180.0 C5—C6—C7—C8 180.0
C1—C2—C3—C5 0.0 C1—C7—C8—C9 180.0
C3—O1—C4—O2 0.0 C6—C7—C8—C9 0.0
C5—O2—C4—O1 0.0 C7—C8—C9—C10 180.0
C4—O2—C5—C6 180.0 C8—C9—C10—O3 0.0
C4—O2—C5—C3 0.0 C8—C9—C10—C11 180.0
O1—C3—C5—C6 180.0 O3—C10—C11—C12 0.0
C2—C3—C5—C6 0.0 C9—C10—C11—C12 180.0
O1—C3—C5—O2 0.0 O3—C10—C11—C13i 119.93 (5)
C2—C3—C5—O2 180.0 C9—C10—C11—C13i −60.07 (5)
O2—C5—C6—C7 180.0 O3—C10—C11—C13 −119.93 (5)
C3—C5—C6—C7 0.0 C9—C10—C11—C13 60.07 (5)
Symmetry code: (i) x, −y+3/2, z.
Hydrogen-bond geometry (Å, º) 
D—H···AD —H H···AD ···AD —H···Asupplementary materials
sup-7 Acta Cryst. (2012). E68, o634    
C2—H2A···O2ii 0.95 (2) 2.56 (2) 3.5092 (12) 179 (1)
Symmetry code: (ii) x−1, y, z.